ProKidney Corp (ticker: PROK) saw its shares surge over 500% on Tuesday following a successful clinical trial of its therapy targeting patients with chronic kidney disease and diabetes. Citi analysts responded to the positive Phase 2 data by reiterating a Buy rating and raising the price target from $6 to $9, highlighting statistical significance in eGFR stabilization and potential upside contingent on FDA clarity. However, Bank of America (BofA) expressed caution, maintaining an Underperform rating with a $1 price target, citing limitations in the REACT study update, including the contribution of group 1 patients matching Phase 3 enrollment, lack of placebo control, and regulatory uncertainty. Morgan Stanley noted that ProKidney has a cash runway through mid-2027, with topline Phase 3 results expected in the third quarter of 2027, but questioned the current market capitalization of $3.5 billion. Additionally, Citi reiterated a Sell rating on Hims & Hers (HIMS) with a $30 price target, due to concerns over limited upside from Canadian expansion and uncertain program economics.